| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(a month from now) | |
| US9339466 | SIGA TECHNOLOGIES | Polymorphic forms of ST-246 and methods of preparation |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(a month from now) | |
| US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(a month from now) | |
| US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(3 years from now) | |
| US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(7 years from now) | |
| US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(7 years from now) | |
| US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(7 years from now) | |
| US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(7 years from now) | |
Tpoxx is owned by Siga Technologies.
Tpoxx contains Tecovirimat.
Tpoxx has a total of 9 drug patents out of which 0 drug patents have expired.
Tpoxx was authorised for market use on 18 May, 2022.
Tpoxx is available in capsule;oral, solution;intravenous dosage forms.
Tpoxx can be used as treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg, tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg.
Drug patent challenges can be filed against Tpoxx from 13 July, 2022.
The generics of Tpoxx are possible to be released after 04 September, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 18 May, 2022
Treatment: Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg; Tpoxx is indicated for the treatment of human smallpox disease in adults and pedia...
Dosage: SOLUTION;INTRAVENOUS; CAPSULE;ORAL
TPOXX family patents
